ADPT
Adaptive Biotechnologies
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 5.34B; Volume: 1.34M; AvgVol 3m: 1.06M; Beta: –;
Cost estimate:
P/E: –; EPS: -0.79; EPS growth quarter/prev quarter: -90.50%;
EPS growth this year: -42.00%; EPS growth past 5 years: ;
EPS ttm: -0.79;
P/S: 73.62; P/B: 11.74; P/Cashflow: 11.90; P/FCF: ;
Sales: 92.17M; Sales growth quarter/prev quarter: -5.00%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 76.30%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -11.20%; ROE – return on equity: -17.80%; LT Debt/Equity: 0.00; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 1.40%; Insider Transactions:-66.66%;
Institutional Ownership: 74.60%; Institutional Transactions: 3.98%;
Data update: 07.10.2020.